Fast Five Quiz: Management of Mantle Cell Lymphoma

Elwyn C. Cabebe, MD


November 17, 2021

Various regimens are available for induction therapy for MCL. Guidelines from the National Comprehensive Cancer Network recommend that high-dose therapy be considered for patients with stage II (bulky) disease and stage III-IV disease who show a complete or partial response to induction therapy. Patients should then be considered for autologous stem cell transplant (SCT).

According to a 2015 consensus statement from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation and the European MCL Network (EBMT/EMCL), autologous SCT is recommended as the standard first-line consolidation therapy for patients who achieve a complete or partial remission after induction therapy. The EBMT/EMCL supports consideration of allogeneic SCT for patients who experience relapse after autologous SCT.

Learn more about additional MCL management considerations and recommendations.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.